JPMorgan Reiterates Overweight Rating on Mereo BipPharma Group (MREO)

July 10, 2025 6:48 AM EDT Send to a Friend
JPMorgan analyst Priyanka Grover reiterated an Overweight rating and $7.00 price target on Mereo BipPharma Group (NASDAQ: MREO)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login